Background: Prior to COVID-19, little was known about how risks associated with such a pandemic would compete with and influence patient decision making regarding cancer risk reducing medical decision making. We investigated how the pandemic affected preferences for medical risk-reducing strategies among women at elevated risk of breast or ovarian cancer.

Methods: We conducted a discrete choice experiment. Women about to undergo genetic testing and counseling at 2 medical centers participated. Enrollment occurred between 2019 and 2022, allowing us to investigate changes in preferences from before the pandemic to after the pandemic. Women chose from permuted scenarios that specified type of surgery, age of menopause, quality of menopausal symptoms, and risk of ovarian cancer, heart disease, or osteoporosis.

Results: A total of 355 women, with a median age of 36 y, participated. In 2019, women were less likely to choose prevention scenarios with higher ovarian cancer risk (odds ratio [OR] = 0.42 per 10-point increase in risk, 95% confidence interval [CI] 0.22-0.61). In June 2020, the effect of higher ovarian cancer risk scenarios on choice was attenuated (OR = 0.86, 95% CI 0.68-1.04), with the effect becoming more salient again by July 2021 (OR = 0.59, 95% CI 0.52-0.67) ( = 0.039 for test of temporal interaction). No other attribute demonstrated a temporal trend.

Conclusion: The risks associated with the COVID-19 pandemic may have attenuated the impact of risk of ovarian cancer on choice of risk-reducing prevention strategies for ovarian cancer. The maximum attenuation occurred at the beginning of the pandemic when access to risk-reducing surgery was most restricted. Our findings highlight how individuals evaluate competing health risks and adjust their uptake of cancer prevention strategies when faced with a future pandemic or similar global crisis.

Highlights: In this discrete choice experiment, women were much less likely to choose prevention scenarios that had higher ovarian cancer risk prior to the COVID-19 pandemic than after the pandemic.The attenuation of preferences may have persisted through 2022.COVID-19 may have altered the relative importance of factors that motivate women to undergo risk-reducing surgeries.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X241302829DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
28
cancer risk
16
prevention strategies
12
covid-19 pandemic
12
discrete choice
12
choice experiment
12
higher ovarian
12
cancer
9
pandemic
9
ovarian
8

Similar Publications

Background & Aims: Surgery combined with chemotherapy remains the mainstay of treatment for advanced epithelial ovarian cancer. It is important to evaluate the occurrence of postoperative complications before operation and to prevent them. The purpose of this study is to investigate the role of sarcopenia diagnosed by CT scans in predicting postoperative complications in patients with ovarian cancer.

View Article and Find Full Text PDF

SETD7 promotes LC3B methylation and degradation in ovarian cancer.

J Biol Chem

December 2024

Department of Basic Medicine, School of Medicine, Jiangsu University, Zhenjiang 212013, Jiangsu, China. Electronic address:

Microtubule-associated protein 1 light chain 3 (LC3) is a key autophagy-related protein involved in regulating autophagosome formation and autophagy activity. Post-translational modifications of LC3 are necessary to modulate its function. However, LC3 protein methylation and its physiological significance have not yet been elucidated.

View Article and Find Full Text PDF

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER.

Georgian Med News

October 2024

1Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Kyoto city, Kyoto; 3Seeds Development and Research Platform Project, Japan Agency for Medical Research and Development (AMED), Chiyoda-ku, Tokyo; 4Kyoto University Graduate School of Medicine, Kyoto city, Kyoto, Japan.

Endosalpingiosis occurs in relatively young women. The incidence of endosalpingiosis exceeds that of other diseases affecting female tissues. As endosalpingiosis is a benign tumor, several women with endosalpingiosis are asymptomatic.

View Article and Find Full Text PDF

Background: No conceptually new drugs for the safe and successful cure of endometriosis are likely to become available soon. Hormonal modulation of ovarian function and suppression of menstruation remain the pillars of disease control. However, existing drugs may be used following novel modalities to limit the consequences of endometriosis progression.

View Article and Find Full Text PDF

Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis.

Eur J Obstet Gynecol Reprod Biol

December 2024

Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Bari, Italy; Gynaecologic Oncology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.

Background: Poly (ADP-ribose) polymerase inhibitors (PARPis) are effective treatment options for patients with advanced ovarian cancer (OC). A typical adverse event (AE) of these agents is haematological toxicity, which represents the leading cause of treatment modification and discontinuation. This systematic review and meta-analysis aimed to analyse the risk of haematological AEs, including anaemia, neutropenia and thrombocytopenia due to the use of PARPis in patients with OC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!